Idera Pharmaceuticals to Present at Canaccord Adams 27th Annual Global Growth Conference
03 Août 2007 - 2:00PM
Business Wire
Idera Pharmaceuticals, Inc. (AMEX: IDP) today announced that Robert
Karr, M.D., President of Idera, will discuss the Company�s
Toll-Like Receptor - targeted drug discovery and development
programs and provide a general corporate overview at the Canaccord
Adams 27th Annual Global Growth Conference taking place August 7-9,
2007, in Boston, MA. The presentation will begin at 2:30 p.m. EDT
on Wednesday, August 8, 2007. The presentation will be available
via live audio webcast on the Company�s website at
www.iderapharma.com. Archived replays will also be located on the
Company�s site following the event. About Idera Pharmaceuticals,
Inc. Idera Pharmaceuticals is a drug discovery and development
company that is developing drug candidates to treat cancer and
infectious, respiratory, and autoimmune diseases, and for use as
vaccine adjuvants. Idera�s proprietary drug candidates are designed
to modulate TLRs, the body�s first line of immune defense. Idera�s
pioneering DNA chemistry expertise enables it to identify drug
candidates for internal development and creates opportunities for
multiple collaborative alliances. Idera�s most advanced clinical
candidate, IMO-2055, is an agonist of TLR9 and is currently in a
Phase 2 trial in oncology and in a Phase 1/2 chemotherapy
combination trial in oncology. Idera has selected a second TLR9
agonist, IMO-2125, as a lead candidate for treating hepatitis C
virus infection. Idera is collaborating with Novartis International
Pharmaceutical, Ltd. for the discovery, development, and
commercialization of TLR9 agonists for the treatment of asthma and
allergy indications. Idera is also collaborating with Merck &
Co., Inc. for the use of Idera�s TLR7, 8 and 9 agonists in
combination with Merck�s therapeutic and prophylactic vaccines in
the areas of oncology, infectious diseases, and Alzheimer�s
disease. For more information, visit www.iderapharma.com. Forward
Looking Statements This press release contains forward-looking
statements concerning Idera Pharmaceuticals, Inc. that involve a
number of risks and uncertainties. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed to be forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"estimates," "intends," "should," "could," "will," "may," and
similar expressions are intended to identify forward-looking
statements. There are a number of important factors that could
cause Idera�s actual results to differ materially from those
indicated by such forward-looking statements, including whether
products based on Idera�s technology will advance into or through
the clinical trial process on a timely basis or at all and receive
approval from the United States Food and Drug Administration or
equivalent foreign regulatory agencies; whether the Company will
complete enrollment of clinical trials or announce trial results in
the time expected; whether, if the Company�s products receive
approval, they will be successfully distributed and marketed;
whether the results of preclinical studies will be indicative of
results that may be obtained in clinical trials; whether the
Company�s collaborations with Novartis and Merck will be
successful; whether the patents and patent applications owned or
licensed by Idera will protect the Company�s technology and prevent
others from infringing it; whether Idera�s cash resources will be
sufficient to fund product development and clinical trials; and
such other important factors as are set forth under the caption
"Risk Factors" in Idera�s Quarterly Report on Form 10-Q filed on
August 1, 2007, which important factors are incorporated herein by
reference. Idera disclaims any intention or obligation to update
any forward-looking statements.
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Idera Pharmaceutical (AMEX:IDP)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Idera Pharmaceuticals (American Stock Exchange): 0 recent articles
Plus d'articles sur Idera Pharmaceuticals, Inc.